Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.

被引：0
|
作者：
Smith, D. M.
Legoux, J.
Brunet, R.
Adhoute, X.
Blanc, J.
Fonck, M.
Vendrely, V.
Becouarn, Y.
机构：
[1] Hop St Andre, Bordeaux, France
[2] Hop Haut Leveque, Pessac, France
[3] Inst Bergonie, Bordeaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3558
引用
收藏
页码：160S / 160S
页数：1
相关论文
共 50 条
  • [1] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [2] FIRST LINE CHEMOTHERAPY (FLC) USING IRINOTECAN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFIRI) COMBINED WITH BEVACIZUMAB IN MEATASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 62 - 62
  • [3] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
    Andric, Z.
    Murtezani, Z.
    Kovcin, V
    Gutovic, J.
    Kostic, S.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
  • [4] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    [J]. MEDICAL ONCOLOGY, 2014, 31 (07)
  • [5] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    [J]. Medical Oncology, 2014, 31
  • [6] Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)
    Folprecht, G.
    Lutz, M. P.
    Schoeffski, P.
    Seufferlein, T.
    Nolting, A.
    Pollert, P.
    Koehne, C.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 199
  • [7] FIRST LINE CHEMOTHERAPY (FLC) USING OXALIPLATIN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFOX-4) COMBINED WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Man, S.
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 66 - 66
  • [8] TREATMENT OF ADVANCED MALIGNANCY WITH 5-FLUOROURACIL (5-FU) COMBINED WITH FOLINIC ACID (FA)
    LOPEZ, AR
    VANTILBURG, A
    BRADLEY, T
    JENSEN, B
    ZIEGLER, J
    ENGELBERG, C
    DEISSEROTH, A
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 178 - 178
  • [9] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    S Falk
    D Jackson
    [J]. British Journal of Cancer, 2002, 86 : 1677 - 1683
  • [10] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    Cunningham, D
    Falk, S
    Jackson, D
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (11) : 1677 - 1683
12345